PIA
ANAB icon

Piedmont Investment Advisors’s AnaptysBio ANAB Stock Holding History

Piedmont Investment Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-322
Closed -$23K – 1098
2018
Q2 		$23K Buy
+322
New +$27K ﹤0.01% 1542

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Piedmont Investment Advisors's ANAB Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of AnaptysBio (ANAB) in Q3 2018, closing a stake of 322 shares — an estimated $23K sold.

Piedmont Investment Advisors first reported a position in ANAB in Q2 2018 and held it in 1 quarter. The position peaked at $23K in Q2 2018. 129 funds tracked by Wall St. Rank hold ANAB as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining AnaptysBio position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 322 AnaptysBio shares in Q3 2018, an estimated $23K.
  • Piedmont Investment Advisors first reported a position in AnaptysBio in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's AnaptysBio position peaked at $23K in Q2 2018.
  • 129 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.